HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV)

HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV) Liste de produits

Attribut
Protein (5)
Bibliothèque de produits
En ligne (5)
Espèces
Human (5)
Étiquette
His Tag (2)Flag Tag & Avi Tag (2)Flag Tag (1)
Marqueur
PE Labeled (1)APC Labeled (1)Biotin-labeled (1)Unconjugated (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT HL1-HA2H8	Human	HEK293	APC-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein	Ajouter au panier
HL1-H52C6	Human	HEK293	Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (MALS & SPR verified)	Ajouter au panier
HL1-H52T3	Human	HEK293	Unconjugated Human HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV) Complex Protein (Monomer, MALS verified)	Ajouter au panier
HL1-H82T3	Human	HEK293	Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein (Monomer, MALS verified)	Ajouter au panier
HL1-HP2E6	Human	HEK293	PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein	Ajouter au panier

Quantité totale5

HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV)Contexte de la molécule

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
ATL-1102	ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102	Phase 2 Clinical	Ionis Pharmaceuticals Inc	Multiple Sclerosis; Muscular Dystrophy, Duchenne	Details
BIIB-107(Biogen)	BIIB-107	Phase 1 Clinical	Biogen Inc	Multiple Sclerosis	Details
ELND-004	ELND-004	Phase 1 Clinical	Perrigo Company Plc	Autoimmune Diseases	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Natalizumab biosimilar(Polpharma Biologics)	PB-006; DST-356A1	Approved	Polpharma Biologics Sa	Tyruko	United States	Crohn Disease; Multiple Sclerosis	Sandoz Inc	2023-08-24	Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease	Details